bird-flu-stocks-logo
birdflustocks.com
bird flu stocks
birdflustocks.com » bird flu stocks  » 
bird flu stocks
GSK/BioNTech/Pfizer: Additional mRNA litigation
By admin | |
Shortly after winning a stay on a COVID-19 vaccine patent
Cidara Therapeutics: Cidara Therapeutics reacquires global rights to CD388 from Johnson & Johnson, announces financing of 240 million USD, will proceed with CD388 phase 2b study in autumn 2024
By admin | |
Cidara Therapeutics (...) today announced that it has entered into
Cidara Therapeutics: Divestiture of rezafungin to focus on Cloudbreak DFC pipeline, including CD388
By admin | |
https://www.cidara.com/news/cidara-therapeutics-announces-divestiture-of-rezafungin-to-mundipharma-to-focus-on-advancing-the-clinical-development-of-cloudbreak-dfc-pipeline
CureVac/GSK: Start of combined phase 1/2 study for avian influenza (H5N1) mRNA vaccine
By admin | |
CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 study
By admin | |
SAB Biotherapeutics: Partnership with Naval Medical Research Center for SAB-176 study
By admin | |
SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a
Vir Biotechnology/GSK: Antibody cooperation ended
By admin | |
The partners have ended their collaboration on anti-influenza antibodies, freeing
BioNTech/CureVac: German court voids CureVac patent after BioNTech challenge, stock drops 41%
By admin | |
https://www.maucherjenkins.com/commentary/first-instance-declares-german-curevac-patent-on-mrna-vaccine-against-covid-19-invalid
BioNTech/Moderna: EPO revokes Moderna patent in vaccine dispute with BioNTech
By admin | |
GSK: GSK sells Haleon shares to sharpen its focus on vaccines and infectious diseases
By admin | |
GSK raises $1.1 billion from Haleon stake sale https://www.reuters.com/markets/deals/gsk-raises-886-mln-pounds-haleon-stake-sale-2023-10-06/
1 2 3 4